Kardium Enrolls First Patient in Globe Registry
Overlake Medical Center in Bellevue activated the inaugural site for the new heart health study.
Updated on Oct. 21, 2026 in Heart Disease
Live Poll
Should all new medical devices be subject to mandatory long-term real-world effectiveness registries?
Kardium has officially enrolled its first patient in the Globe Registry, a multicenter study evaluating the Globe Pulsed Field System. Overlake Medical Center in Bellevue serves as the first site to begin participating in this observational research.
Why it matters
The registry aims to capture critical real-world data on the safety and effectiveness of the Globe System, which integrates cardiac mapping and ablation into one catheter. This study follows previous regulatory approvals in both the United States and Canada.
The registry anticipates enrolling a total of 500 patients across multiple centers. Each participant will undergo follow-up evaluations over a period of 12 months post-procedure.
The players
Kardium
Kardium is a medical device company based in Vancouver that specializes in developing innovative solutions for the treatment of atrial fibrillation.
Overlake Medical Center
Overlake Medical Center is a non-profit regional healthcare system located in Bellevue that provides a wide range of advanced medical services.
The details
The Globe Pulsed Field System combines mapping and ablation technology into a single catheter to treat heart conditions. As a prospective, single-arm observational study, the registry provides a platform to monitor device performance following its commercial launch.
Timeline
August 2025: The U.S. Food and Drug Administration approved the Globe System.
July 2026: Health Canada approved the Globe System.
October 21, 2026: The first patient was enrolled in the Globe Registry.
Health Landscape
This registry aligns with the industry-standard approach for post-market surveillance of medical technology. It follows the regulatory framework set by the FDA's post-market surveillance requirements to ensure long-term device safety.
The registry provides a framework for monitoring the performance of integrated ablation technology in a clinical environment. Participants at Overlake Medical Center will receive structured 12-month follow-up care to track their health outcomes.
The takeaway
The launch of the Globe Registry marks a significant step in verifying the real-world performance of new cardiac catheter technology. Patients and providers should look toward upcoming data releases to understand the long-term effectiveness of these ablation systems.
Further reading
Find more information on local cardiac care initiatives on the Heart Disease page.
Live Poll
Should all new medical devices be subject to mandatory long-term real-world effectiveness registries?
